Search Results - "Maroto, P."

Long-term toxicity of the treatment for germ cell-cancer. A review by Maroto, P., Anguera, G., Martin, C.

“…Testicular germ-cell cancer (GCC) is a curable disease. Stage I patients are mostly cured by surgery alone. For those with good prognosis advanced disease,…”
Get full text

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) by Aparicio, J., Maroto, P., García del Muro, X., Sánchez-Muñoz, A., Gumà, J., Margelí, M., Sáenz, A., Sagastibelza, N., Castellano, D., Arranz, J.A., Hervás, D., Bastús, R., Fernández-Aramburo, A., Sastre, J., Terrasa, J., López-Brea, M., Dorca, J., Almenar, D., Carles, J., Hernández, A., Germà, J.R.

“…We aimed to analyze prognostic factors for relapse in stage I seminoma managed by either active surveillance or adjuvant chemotherapy, and to describe the…”
Get full text

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action by Duran, I., Lambea, J., Maroto, P., González-Larriba, J. L., Flores, Luis, Granados-Principal, S., Graupera, M., Sáez, B., Vivancos, A., Casanovas, O.

“…Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several genes. Loss of function of the von Hippel-Lindau ( VHL ) tumour…”
Get full text

Simple Schizophrenia or Neurotic Disorder? Case report by Suz Maroto, P., Díez Valle, B., Hurtado De Mendoza Vázquez, A., Navas Collado, E.

“…Introduction The diagnosis of simple schizophrenia remains an unusual and controversial diagnosis today. The presentation of nonspecific symptoms shared by…”
Get full text

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity by Bellmunt, J., González-Larriba, J.L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez-Gracia, J.L., Aguilar, G., Villanueva, X., Albanell, J., Calvo, A.

“…A strong rationale supports the role of antiangiogenic drugs in urothelial cancer. This trial was designed to assess the activity of sunitinib as first-line…”
Get full text

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer by de Liaño, A G, Reig, O, Mellado, B, Martin, C, Rull, E U, Maroto, J P

“…Background: Biomarkers for metastatic castration-resistant prostatic cancer (mCRPC) are an unmet medical need. Methods: The prognostic and predictive value for…”
Get full text

Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection by Borque-Fernando, Á., Zapatero, A., Manneh, R., Alonso-Gordoa, T., Couñago, F., Domínguez-Esteban, M., López-Valcárcel, M., Rodríguez-Antolín, A., Sala-González, N., Sanmamed, N., Maroto, P.

“…The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen…”
Get full text

Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group by Aparicio, J, Sánchez-Muñoz, A, Ochenduszko, S, Gumà, J, Fernández-Aramburo, A, García Del Muro, X, Quiroga, V, Sastre, J, Alonso-Gordoa, T, Sagastibelza, N, Maroto, P, Gómez de Liaño, A, Vázquez, S, Diz, P, Durán, I, Domenech, M, Pinto, A, Hernández, A, González-Billalabeitia, E, Terrasa, J

“…Stage IS testicular cancer is defined by the persistence of elevated serum tumor markers, including α-fetoprotein and/or β-human chorionic gonadotropin, after…”
Get full text

Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations by Rodríguez-Vida, A., Pérez-Gracia, J.L., Taus, A., Bonfill, T., Vázquez-Mazón, F.J., Galtes, S., Pons, B., Cano, L., Macia, S., Maroto, P., Bellmunt, J.

Get full text

Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer by Maroto, P, García del Muro, X, Valverde, C, Pinto, A, Sanchez, A, Guma, J, Alonso, T, Martínez del Prado, P, Vazquez, S, Mellado, B, Aparicio, J, Fernandez-Aramburo, A, Girones, R, Terrasa, J

“…•Germ cell cancer is the most frequent solid tumor in young men aged 20 to 40.•Risk factors of a germ cell cancer are age, undescended testis, familial…”
Get full text

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) by González del Alba, A., De Velasco, G., Lainez, N., Maroto, P., Morales-Barrera, R., Muñoz-Langa, J., Pérez-Valderrama, B., Basterretxea, L., Caballero, C., Vazquez, S.

“…The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of…”
Get full text

Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group by Aparicio, J., García del Muro, X., Maroto, P., Terrasa, J., Castellano, D., Bastús, R., Gumà, J., Sagastibeltza, N., Durán, I., Ochenduszko, S., Meana, J. A., García-Sánchez, J., Arranz, J. A., Gironés, R., Germà, J. R.

“…Purpose Active surveillance (AS) and adjuvant chemotherapy (AC) with carboplatin are valid alternatives for managing stage I seminoma, and most relapses can be…”
Get full text

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study by Rodriguez-Vida, A., Valderrama, B.P., Castellano, D., Pinto, A., Mellado, B., Puente, J., Climent, M.A., Domenech, M., Vazquez, F., Perez-Gracia, J.L., Bonfill, T., Morales-Barrera, R., Gonzalez-Billalabeitia, E., Garcia-del-Muro, X., Maroto, P., Navarro-Gorro, N., Juanpere, N., Juan, O., Bellmunt, J.

“…Platinum-based chemotherapy (ChT) has been the standard first-line treatment for metastatic urothelial carcinoma (mUC). The purpose of this study was to…”
Get full text

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy by de Bono, J.S., Molife, L.R., Sonpavde, G., Maroto, J.P., Calvo, E., Cartwright, T.H., Loesch, D.M., Feit, K., Das, A., Zang, E.A., Wanders, J., Agoulnik, S., Petrylak, D.P.

“…Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane…”
Get full text

Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel by Puente, J., Mendez Vidal, M.J., Saez, M.I., Font Pous, A., Duran, I., Castellano, D., Juan Fita, M.J., Santander, C., Arranz Arija, J.A., Sanchez-Hernandez, A., Mellado, B., Alonso, T., Gonzalez del Alba Baamonde, M.A., Maroto, P., Lazaro, M., Esteban, E., Cassinello, J.G., Climent Duran, M.A.

Get full text

2562 Chromogranin A and Enolase levels in serum as prognostic factors in castration prostate cancer resistant by Sala Gonzalez, N, Buxo, M, Mora, J, Maroto, P, Palou, J, Esquena, S, Sancho, G, Barnadas, A

Get full text

2584 Single centre experience with FDG PET-CT vs CT scan in the staging of urothelial neoplasms by de Liaño, A. Gomez, Anguera, G, Duch, J, Estorch, M, Flotats, A, Sancho, G, Palou, J, Gaya, J.M, Algaba, F, Maroto, P

Get full text

Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma by Rodríguez Faba, O, Palou, J, Breda, A, Maroto, P, Fernández Gómez, J M, Wong, A, Villavicencio, H

“…Despite the uncertain value of adjuvant chemotherapy after radical nephroureterectomy (RNU) it is clear that impaired renal function represents a…”
Get more information

SEOM clinical guidelines for the management of germ cell testicular cancer (2016) by Aparicio, J., Terrasa, J., Durán, I., Germà-Lluch, J. R., Gironés, R., González-Billalabeitia, E., Gumà, J., Maroto, P., Pinto, A., García-del-Muro, X.

“…Testicular cancer represents the most common malignancy in males aged 15–34 years and is considered a model of curable neoplasm. Maintaining success, reducing…”
Get full text

2548 The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC) by Chowdhury, S, Birtle, A.J, Bjartell, A, Costa, L, Feyerabend, S, Galli, L, Lumen, N, Kalinka-Warzocha, E, Maroto, P, Matveev, V.B, Paiss, T, Spaeth, D, Klumper, E, Thingstad, T, Wapenaar, R, Lee, E

Get full text